Novasite Pharmaceuticals And The Stanley Medical Research Institute Announce Alliance To Discover Novel Allosteric Modulator Drugs For Schizophrenia
10/19/2005 5:12:22 PM
Novasite Pharmaceuticals, Inc. (Novasite) and The Stanley Medical Research Institute (SMRI), a foundation dedicated to fund research in schizophrenia and bipolar disorders, today announced an alliance to discover novel drugs to treat unmet medical needs in schizophrenia. SMRI will provide clinical guidance and fund research at Novasite, who will discover allosteric modulator drugs for schizophrenia acting on a validated G-Protein Coupled Receptor (GPCR) target. Dr. Michael Knable, the Executive Director of SMRI, and Dr. John Davis, a distinguished member of the SMRI's Scientific Advisory Board (SAB), have joined Novasite's SAB to guide its clinical efforts in schizophrenia and bipolar disorders.
comments powered by